1. A recombinant adenovirus comprising: a polynucleotide encoding a ribozyme complex mediating trans-splicing, and HSVtk (thymidine kinase of herpes simplex virus Human) which acts against the mRNA TERT (telomerase reverse transcriptase) (SEQ ID NO: 1), representing the cancer-specific gene and an anti-cancer therapeutic gen.2. The recombinant adenovirus of claim 1, wherein the polynucleotide encoding the complex comprises a nucleotide sequence of SEQ ID NO: 2, which encodes a ribozyme Rib67, and a polynucleotide of SEQ ID NO: 3, which encodes HSVtk.3. The recombinant adenovirus of claim 1, wherein the anti-cancer therapeutic gene is selected from the group consisting of drug-activating genes, proapoptotic genes, cytostatic genes, cytotoxic genes, tumor suppressor genes, antigenic genes, antiangiogenic genes and cytokine gena.4. The recombinant adenovirus of claim 3, wherein the anti-cancer therapeutic gene comprises a nucleotide sequence of SEQ ID NO: 4 which encodes sPD-1 (soluble protein programmed death 1) .5. A pharmaceutical composition for preventing or treating cancer, comprising as an active ingredient a recombinant adenovirus according to any one pp.1-4.6. A composition according to claim 5, further comprising a pharmaceutically acceptable carrier, excipient or razbavitel.7. A method for treating cancer comprising administering to a patient a pharmaceutically acceptable amount of a recombinant adenovirus according to any one of claims 1-4.1. Рекомбинантный аденовирус, содержащий: полинуклеотид, кодирующий комплекс рибозима, опосредующего транс-сплайсинг, и HSVtk (тимидинкиназы вируса простого герпеса человека), который действует против мРНК TERT (обратной транскриптазы теломеразы) (SEQ ID NO: 1), представляющей рак-специфический ген и противораковый терапевтический ген.2. Рекомбинантный аденовирус по п.1, где полинуклеотид, кодирующий комплекс, содержит нуклеотидную последовательность SEQ ID NO: 2, которая кодирует рибозим Rib67, и полинуклеотид SEQ ID NO:
